Phaseline

Companies › Restorbio

Restorbio: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 2; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dactolisib (BEZ235)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 2Respiratory Tract Infections; Covid19–
Everolimus (RAD001)
FK506-binding protein 1A inhibitor
FKBP1APhase 2Respiratory Tract Infections–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03373903Dactolisib (BEZ235)Phase 2Respiratory Tract InfectionsInfectious diseaseMay 2018
NCT03373903Everolimus (RAD001)Phase 2Respiratory Tract InfectionsInfectious diseaseMay 2018
NCT04584710Dactolisib (BEZ235)Phase 2Covid19Infectious diseaseFeb 2021

Targets

MTOR (1) PIK3R1 (1) PIK3CB (1) PIK3CG (1) PIK3CA (1) FKBP1A (1)

Companies with the same targets

Eli Lilly Celcuity Sovargen Faeth Therapeutics Palvella Therapeutics Novartis iVascular S.L.U. Supernus Pharmaceuticals SAPU NANO (US) AstraZeneca

Companies built like this

WestVac Biopharma Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals Code Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.